An example of effective immune-stroma dual targeting therapy comes from recent work from Claus and colleagues in solid tumors (282), where the combination of tumor antigen-TCB (CEA-TCB) with a stroma-specific/T cell co-stimulatory fusion protein (FAP-4-1BBL) promoted tumor remission and accumulation of activated CD8+ in the TME (Figure 3). The gene discussed is FAP; the disease is neoplasm.